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e-mail address: kbfnyf@aol.com (K.B. Freund).Kavita V. Bhavsar, MD; K. Bailey Freund, MD ⇑AbstractPurpose: To describe the clinical characteristics of a subset of eyes with neovascular age-related macular degeneration (NVAMD)
receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy which retain good visual acuity despite chronic,
persistent subfoveal subretinal fluid (SRF).
Design: Retrospective, observational case series.
Methods: Study eyes were identified from a consecutive series of 186 patients treated with anti-VEGF therapy seen for regular
follow-up over a 3-month period. The clinical histories of 10 eyes of 9 patients with NVAMD, chronic subfoveal SRF despite con-
tinuous anti-VEGF therapy, and good long-term visual acuity of 20/40 or greater were reviewed. Demographic factors, baseline
and final visual acuity, neovascular lesion type, duration of persistent fluid, baseline and final subfoveal choroidal thickness, pres-
ence of geographic atrophy, and number of anti-VEGF injections were analyzed.
Results: The mean age of patients was 78 years (range 55–91). The mean duration of persistent fluid was 5.2 years (range 1.3–
11.0). Long-term visual acuities remained stable at 20/40 or better in all eyes. All eyes had type 1 (sub-retinal pigment epithelial)
neovascularization. Average baseline subfoveal choroidal thickness was 285.3 lm and the average follow-up subfoveal choroidal
thickness was 239.7 lm. No eyes had the presence of geographic atrophy. The mean number of injections was 36.5 (range 17–66).
Conclusion: Some eyes with type 1 neovascularization associated with chronic persistent subfoveal subretinal fluid despite contin-
uous intravitreal anti-VEGF therapy may maintain good long-term visual outcomes. We hypothesize that type 1 neovascularization
and greater subfoveal choroidal thickness may exert a protective effect on photoreceptor integrity. Further studies are necessary
to assess long-term visual prognosis and predictive factors in patients with type 1 neovascularization leading to persistent subret-
inal fluid that is recalcitrant to anti-VEGF treatment.
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Neovascular age-related macular degeneration (AMD) is
characterized by the formation of an abnormal complex ofvascular tissue which leads to visually significant complications
such as hemorrhage or exudation.1 The pathologic mecha-
nisms underlying the formation of choroidal neovasculariza-
tion (CNV) are incompletely understood. The advent ofe:
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classification of CNV which was previously defined by fluores-
cein angiography alone.2 Vascular endothelial growth factor A
(VEGF-A) is a diffusible cytokine implicated in inducing
angiogenesis and increased vascular permeability in the set-
ting of neovascular AMD.3,4 Blockade of VEGF-A has become
an effective treatment for the management of CNV secondary
to AMD.5–10 The employment of anti-VEGF therapy has
improved long term visual outcomes by reducing the risk of
fluid accumulation and hemorrhage.11
However, in a small subset of patients, successful resolu-
tion of anatomic features such as the presence of sub or
intra-retinal fluid may be difficult.12 Current clinical practice
advocates treatment with anti-VEGF to achieve complete or
near complete resolution of foveal threatening fluid to mini-
mize risk of structural damage to retinal photoreceptors.
However, the relationships between morphologic features
and visual prognosis after intravitreal anti-VEGF treatment
are complex and not well characterized.13,14 Integrity of reti-
nal photoreceptor cells may be dependent on a combination
of factors that interact to modify the retinal pigment epithe-
lium and photoreceptor layer.
The purpose of this study is to assess the clinical character-
istics of eyes with neovascular AMD receiving continuous
intravitreal anti-VEGF therapy that retain good visual acuity
despite chronic, persistent, subfoveal subretinal fluid (SRF).
Methods
This study design was approved by Western institutional
review board (Olympia, WA, USA). It complied with the
Health Insurance Portability and Accountability Act of 1996
and followed the tenets of the Declaration of Helsinki.
Study eyes were identified from a consecutive series of
186 NVAMD patients treated with intravitreal anti-VEGF ther-
apy seen for regular follow-up visits over a 3-month period by
a single physician (KBF). All patients had active choroidal
neovascularization documented by SD-OCT and fluorescein
angiography (Topcon, Tokyo, Japan) prior to the initiation
of intravitreal anti-VEGF therapy. To be included in this study,
eyes were required to have chronic subfoveal subretinal fluid
(defined as fluid present at >80% of all follow-up visits for
>1 year) secondary to NVAMD despite continuous anti-VEGF
therapy, and good long-term visual acuity of 20/40 or better.
All patients had undergone a complete ophthalmic examina-
tion including a slit-lamp examination, dilated fundus biomi-
croscopy, and eye-tracked imaging with Spectralis SD-OCT
(Heidelberg Engineering, Vista, California, USA) at eachTable 1. Patient demographics and clinical characteristics.
Age Duration of subretinal
fluid (Years)
Baseline best
corrected
visual acuity
Patient 1 85 5.0 20/30
Patient 2 87 9.5 20/25
Patient 3 81 4.9 20/25
Patient 4 91 11.0 20/30
Patient 5 79 1.5 20/30
Patient 6 84 7.0 20/30
Patient 7 68 1.3 20/60
Patient 8 55 2.5 20/30
Patient 9 (OD) 75 4.9 20/30
Patient 9 (OS) 75 4.9 20/40office visit. Eyes with concomitant retinal disease including
diabetic retinopathy, pathologic myopia, angioid streaks,
and retinal vascular occlusions were excluded. A retrospec-
tive chart review was performed to obtain data on demo-
graphics and treatment history (photodynamic therapy,
number and type of anti-VEGF injections).
Spectralis SD-OCT was used to obtain measurements of
subfoveal choroidal thickness. Choroidal thickness was manu-
ally measured beneath the foveal center from the posterior
edge of the retinal pigment epithelium to the choroid/sclera
junction using a linear measuring tool built-into the review
software. SD-OCT scans were also qualitatively assessed for
integrity of the ellipsoid zone and external limiting mem-
brane, presence of cystoid macular edema, location of subret-
inal fluid, and characterization of choroidal neovascularization
subtype (1 – sub-RPE, 2 – subretinal, 3 – intraretinal/retinal
angiomatous proliferation or mixed) in all patients.
Results
From the 186 consecutive NVAMD patients seen over
3 months, a total of 9 (4.8%) patients (10 eyes) with chronic
subretinal fluid were identified for this study (Table 1). The
mean patient age was 78 years (range 55–91). Of these sub-
jects, 3 were male and 6 were female. All patients were white.
In addition to neovascular AMD, the only other ocular comor-
bidity shared by these patients was the presence of nuclear
sclerotic cataracts. 5 eyes of 4 patients had nuclear sclerotic
cataracts and the remaining 5 eyes of 5 patients had under-
gone uncomplicated cataract surgery with posterior chamber
intraocular lens placement.
SD-OCT data showed the presence of vascularized pig-
ment epithelial detachment (PED) consistent with type 1 neo-
vascularization in all eyes and baseline fluorescein
angiography was consistent with type 1 neovascularization
in all eyes (Fig. 1A–D). All 10 eyes had subfoveal subretinal
fluid, and 1 eye also had an additional area of subretinal fluid
located temporal to the fovea. The mean duration of persis-
tent subretinal fluid was 5.2 years (range 1.3–11.0). Only 1
eye had or developed cystoid macular edema detected by
SD-OCT. At least partial preservation of the foveal ellipsoid
zone and external limiting membrane was identified in all pa-
tients. No eyes had or developed the presence of foveal or
non-foveal geographic atrophy over the follow-up period.
Reliable measurements of choroidal thickness were at-
tained in all cases. Mean baseline subfoveal choroidal thick-
ness was measured to be 285.3 lm (range 100–573 lm) and
the mean follow-up subfoveal choroidal thickness wasFollow-up best
corrected
visual acuity
Baseline choroidal
thickness (lm)
Choroidal
neovascularization
subtype (1, 2, 3)
20/40 100 1
20/25 289 1
20/25 231 1
20/30 174 1
20/25 326 1
20/30 427 1
20/25 258 1
20/30 573 1
20/25 238 1
20/30 237 1
Figure 1. Retinal imaging of patient 1 at presentation and follow-up. (A) Color photograph of patient 1 at presentation reveals an elevated vascularized
pigment epithelial detachment and drusen. (B) Fundus autofluorescence image of patient 1 at 5-year follow-up reveals no geographic atrophy. (C)
Spectral domain optical coherence tomography shows subfoveal subretinal fluid over a vascularized pigment epithelial detachment at (i) presentation
and (ii) 5-year follow-up. (D) Baseline fluorescein angiography confirms the presence of active type 1 neovascularization prior to treatment.
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choroidal thickness were obtained from another study which
measured choroidal thickness in 42 eyes of 42 healthy sub-
jects.14 These subjects had no history of retinal or choroidal
pathology, and patients with myopic refractive error of great-
er than 6.0 diopters were excluded. The average subfoveal
choroidal thickness in this group of healthy patients was mea-
sured to be 256.8 ± 75.8 lm (Fig. 2).
All eyes were being treated with intravitreal anti-VEGF
therapy in order to control their disease (Table 2). Eyes had
received a mean of 36.5 injections (range 17–66) of either
bevacizumab (intra-vitreal 1.25 mg/0.05 ml), ranibizumab (in-
tra-vitreal 0.5 mg/0.05 ml), or aflibercept (2.0 mg/0.05 ml).
Only a single eye had received verteporfin photodynamicFigure 2. Average subfoveal choroidal thickness in healthy, normal eyes
compared to enrolled study subjects.therapy (PDT) prior to the initation of intravitreal therapy,
with a total of 5 treatment sessions, including one session
of combined PDT and intra-vitreal triamcinolone acetonide.
At the most recent follow-up, 7 eyes were receiving intravi-
treal monthly aflibercept and the remaining 3 eyes were
receiving monthly intravitreal ranibizumab. Criteria for
retreatment included persistent subretinal or intraretinal fluid
by OCT with or without the presence of clinically identified
hemorrhage.Discussion
This study illustrates that good long-term visual outcomes
are possible in certain eyes with persistent subretinal fluid
secondary to type 1 neovascularization in the setting of
NVAMD. While morphologic features detected by SD-OCT
are typically used to guide intravitreal anti-VEGF therapy,
their relationship to visual prognosis may be complex and
incompletely characterized.
Jaffe et al. investigated the association of macular mor-
phology with visual acuity in eyes with neovascular AMD trea-
ted with intravitreal ranibizumab or bevacizumab for 1 year.15
The results of their study indicated that residual intraretinal
fluid in the macula, mainly intraretinal fluid involving the fo-
vea, had a significant negative effect on visual acuity, whereas
subretinal or sub-retinal pigment epithelial (RPE) fluid was
not found to have a significant negative effect on visual func-
tion. Previous studies have also reported that cystoid macular
edema has an adverse impact on visual acuity when associ-
ated with subfoveal CNV.16 The etiology of this specific neg-
ative effect of intraretinal fluid (not subretinal or sub-RPE
Table 2. Treatment Histories of Study Subjects.
Total # of anti-VEGF injections % Bevacizumab % Ranibizumab % Aflibercept Total # PDT Total # of PDT + IVK
Patient 1 66.0 – 72.7 27.3 – –
Patient 2 65.0 3.0 95.4 1.5 – –
Patient 3 55.0 – 65.5 34.6 – –
Patient 4 64.0 – 96.9 3.1 4 1
Patient 5 17.0 – 88.2 11.8 – –
Patient 6 17.0 – 5.9 94.1 – –
Patient 7 21.0 – 19.1 71.4 – –
Patient 8 26.0 – 11.5 88.5 – –
Patient 9 (OD) 17.0 – – 100.0 – –
Patient 9 (OS) 17.0 – – 100.0 – –
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may simply be a manifestation of irreversible photoreceptor
damage, rather than its cause. Our study further supports
the possibility that persistent subretinal fluid may not always
have a progressive impact on visual outcomes. Moreover,
one subject in this study had intraretinal fluid inferior to the
fovea in addition to the presence of subretinal fluid and
was able to maintain a visual acuity of 20/25 at 5 year fol-
low-up.
A cone-specific, RPE-independent, pigment regeneration
pathway may explain the relative integrity of photoreceptor
function despite chronic subretinal fluid accumulation. In pri-
mate and human models, an intraretinal visual cycle has been
proposed to play an important role in preserving cone func-
tion in pathologic states that selectively impair the estab-
lished RPE visual cycle.17 Following photolysis,
chromophore molecules may bypass an RPE dependent pro-
cess, instead undergoing recycling in the Müller cells of the
retina. Subsequently, the molecules are supplied to cones
in order to complete the cycle of pigment regeneration. Per-
sistent subretinal fluid may mechanically inhibit the RPE
dependent pathway, but could allow or even theoretically
augment the intraretinal pathway through diffusion of neces-
sary substrates to Müller cells.
It is pertinent to note that the average subfoveal choroidal
thickness in our study subjects was greater than expected for
patients with macular degeneration on long-term intravitreal
anti-VEGF therapy. Branchini et al. found mean subfoveal
choroidal thickness to be 171.8 lm in 22 patients with neo-
vascular AMD treated with anti-VEGF therapy for one year.18
Risk of geographic atrophy and resultant poor visual progno-
sis is a significant concern in NVAMD patients with chronic
anti-VEGF treatment due its potential atrophic effects on
the choroid, RPE, and photoreceptor layer.19 Increased cho-
roidal thickness may provide greater nourishment to the out-
er retina and facilitate enhanced function of retinal
photoreceptor cells.20,21 This may help explain the lack of
geographic atrophy in all studied eyes.
Interestingly, all subjects also had type 1 neovasculariza-
tion. We hypothesize that the sub-RPE neovascular complex
may deliver nutrients to the outer retina without invading
the subretinal space and damaging adjacent delicate struc-
tures, such as the photoreceptor layer. Type 1 neovasculari-
zation could theoretically be protective against geographic
atrophy. Future investigations need to be performed to elu-
cidate the relationship between anatomic neovascular sub-
types, risk of geographic atrophy, and visual prognosis.
Further large scale, prospective studies could also address
the limitations present in our study. First, due to the rarity of
cases, the sample size of our study was limited to only 10eyes of 9 patients. Future dedicated investigations of choroi-
dal thickness might include matched control eyes. Addition-
ally, measurements of 500-lm intervals up to 2500 lm
temporal and nasal to the fovea should be obtained, and
all measurements should be performed by 2 independent
observers. These measurements can then be compared using
paired t-test in order to verify statistical significance. Another
limitation of our study is that there was not a standard proto-
col for initiation of therapy or the timing and number of injec-
tions or PDT treatments.
In this investigation, patients with type 1 neovasculariza-
tion causing persistent subretinal fluid refractory to anti-
VEGF therapy were able to achieve good long-term visual
outcomes. Increased subfoveal choroidal thickness and type
1 neovascularization may exert a protective effect on photo-
receptor integrity and may result in better visual outcomes.Financial interest disclosure
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